Kilitch Drugs (India) Investor Sentiment

KILITCH Stock   310.65  3.25  1.06%   
Under 51% of Kilitch Drugs' investor base is interested to short. The analysis of overall sentiment of trading Kilitch Drugs Limited stock suggests that many investors are impartial at this time. Kilitch Drugs' investing sentiment shows overall attitude of investors towards Kilitch Drugs Limited.
  
over two weeks ago at news.google.com         
Kilitch Drugs Standalone September 2024 Net Sales at Rs 45.35 crore, up 43.63 percent Y-o-Y - Moneyc...
Google News at Macroaxis
over two weeks ago at news.google.com         
Pharma stock jumps 14 percent after reporting 7718 percent QoQ increase in net profits - Trade Brain...
Google News at Macroaxis
over two months ago at news.google.com         
Do Its Financials Have Any Role To Play In Driving Kilitch Drugs Limiteds Stock Up Recently - Simply...
Google News at Macroaxis
over two months ago at news.google.com         
KILITCH DRUGS Share Price Today Up 6 percent - Equitymaster
Google News at Macroaxis
over three months ago at news.google.com         
Kilitch Drugs Consolidated June 2024 Net Sales at Rs 33.45 crore, down 8.49 percent Y-o-Y - Moneycon...
Google News at Macroaxis
over three months ago at news.google.com         
Kilitch Drugs consolidated net profit declines 60.12 percent in the June 2024 quarter - Business Sta...
Google News at Macroaxis
over three months ago at news.google.com         
Kilitch Drugs Downgraded to Sell by MarketsMOJO Factors to Consider - MarketsMojo
Google News at Macroaxis
over three months ago at news.google.com         
Kilitch Drugs Limited Not Flying Under The Radar - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
Krebs Biochemicals Industries Ltd leads gainers in B group - Business Standard
Google News at Macroaxis
over six months ago at news.google.com         
Kwality Pharmaceuticals Ltd Share Price Today Kwality Pharmaceuticals Ltd Stock Price Live NSEBSE, K...
Google News at Macroaxis
over six months ago at news.google.com         
Kilitch Drugs Standalone March 2024 Net Sales at Rs .14 crore, down 9.58 percent Y-o-Y - Moneycontro...
Google News at Macroaxis
over six months ago at news.google.com         
Kilitch Drugs consolidated net profit rises 0.84 percent in the March 2024 quarter - Business Standa...
Google News at Macroaxis
over six months ago at news.google.com         
Results Calendar For May 27 NSE, BSE companies announcing Q4 FY 2024 earnings on Monday - FULL list ...
Google News at Macroaxis
over six months ago at news.google.com         
The FDA serves up warning letters to pair of Indian pharmas - FiercePharma
Google News at Macroaxis
over six months ago at news.google.com         
Kilitch Drugs Ltd Share Price Today Kilitch Drugs Ltd Stock Price Live NSEBSE, Kilitch Drugs Ltd ......
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Kilitch Drugs that are available to investors today. That information is available publicly through Kilitch media outlets and privately through word of mouth or via Kilitch internal channels. However, regardless of the origin, that massive amount of Kilitch data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kilitch Drugs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kilitch Drugs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kilitch Drugs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kilitch Drugs alpha.

Kilitch Drugs Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
KILITCH DRUGS Share Price Today Up 6 percent - Equitymaster
09/10/2024
2
Kilitch Drugs Standalone September 2024 Net Sales at Rs 45.35 crore, up 43.63 percent Y-o-Y - Moneycontrol
11/13/2024

Complementary Tools for Kilitch Stock analysis

When running Kilitch Drugs' price analysis, check to measure Kilitch Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kilitch Drugs is operating at the current time. Most of Kilitch Drugs' value examination focuses on studying past and present price action to predict the probability of Kilitch Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kilitch Drugs' price. Additionally, you may evaluate how the addition of Kilitch Drugs to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges